Pfizer Inc., Groton, CT, USA.
Toxicol Pathol. 2022 Feb;50(2):266-273. doi: 10.1177/01926233211061712. Epub 2021 Dec 7.
Identification of bone marrow toxicity is an important issue in drug development and toxicologic pathologists play a critical role in that identification. Knowledge of the general components of bone marrow, relevant anatomical and species differences, and the standard approach (routine systematic histological evaluation of the bone marrow in conjunction with analysis of the peripheral complete blood count data) will be reviewed. Specific morphologic features that anatomic pathologists should look for in the various components of bone marrow as well as suggested terminology for bone marrow findings will be discussed. Finally, an opinion on the limitations of the standard approach to bone marrow evaluation will be provided including general recommendations on when additional methods (image analysis of hematoxylin and eosin stained slides, flow cytometry or Sysmex XT 2000iV analysis, cytological evaluation of bone marrow smears, in vitro models, and transmission electron microscopy) might be useful in the detection or further characterization of bone marrow toxicity. [Box: see text].
骨髓毒性的鉴定是药物开发中的一个重要问题，毒理病理学家在这一鉴定中起着至关重要的作用。本文将回顾骨髓的一般组成部分、相关的解剖学和物种差异，以及标准方法（结合外周全血细胞计数数据对骨髓进行常规系统组织学评估）。本文还将讨论解剖病理学家在骨髓的各种成分中应寻找的特定形态特征，以及骨髓发现的建议术语。最后，本文将就骨髓评估的标准方法的局限性提出意见，包括关于何时可能需要额外的方法（苏木精和伊红染色切片的图像分析、流式细胞术或 Sysmex XT 2000iV 分析、骨髓涂片的细胞学评估、体外模型和透射电子显微镜）来检测或进一步表征骨髓毒性的一般建议。[方框：见正文]。
